首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia
【2h】

Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia

机译:使用BRAF V600E突变特异性抗体的免疫组织化学分析对毛细胞白血病的诊断高度敏感且具有特异性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hairy cell leukemia (HCL) is usually diagnosed by morphology and flow cytometry studies. However, it is challenging sometimes to distinguish HCL from its mimics. Recently, the BRAF V600E mutation has been described as a disease-defining molecular marker for HCL which is present in nearly all cases of HCL but virtually absent in mimics of HCL. In this study, we investigated the possibility of using immunohistochemical detection of the BRAF V600E mutant protein to differentiate HCL from its mimics. A total of twenty-eight FFPE tissue specimens were studied, including HCL (n=12), HCL variant (HCL-v, n=3), splenic marginal zone lymphoma (SMZL, n=6), and other marginal zone lymphomas (MZL, n=7). Immunohistochemical studies were performed using a mouse monoclonal antibody (clone VE1, Spring Bioscience, CA) specific for BRAF V600E mutation. Molecularly confirmed BRAF V600E mutation positive and negative cases were used as the positive and negative controls respectively. All 12 cases of HCL showed cytoplasmic BRAF V600E protein expression in leukemia cells by immunohistochemical study regardless of tumor burden, whereas all cases of HCL mimics including HCL-v, SMZL, and MZL were negative for BRAF V600E protein. Using this BRAF V600E mutation specific antibody, this immunohistochemical study has 100% sensitivity and 100% specificity for the diagnosis of HCL in our cohort. In conclusion, immunohistochemical detection of the BRAF V600E mutant protein is highly sensitive and specific for the diagnosis of HCL. Compared to PCR or sequencing-based methodologies, immunohistochemistry is a relatively rapid and inexpensive alternative for the differential diagnosis between HCL and its mimics.
机译:通常通过形态学和流式细胞术研究来诊断毛细胞白血病(HCL)。但是,有时很难将HCL与它的模拟物区分开。最近,BRAF V600E突变已被描述为HCL的疾病分子标记,几乎在所有HCL病例中都存在,但在HCL的模拟物中几乎不存在。在这项研究中,我们调查了使用BRAF V600E突变蛋白的免疫组织化学检测方法将HCL与它的模拟物区分开的可能性。共研究了28个FFPE组织标本,包括HCL(n = 12),HCL变体(HCL-v,n = 3),脾边缘区淋巴瘤(SMZL,n = 6)和其他边缘区淋巴瘤( MZL,n = 7)。使用特异性针对BRAF V600E突变的小鼠单克隆抗体(VE1克隆,Spring Bioscience,CA)进行了免疫组织化学研究。分子确诊的BRAF V600E突变阳性和阴性病例分别用作阳性和阴性对照。不论肿瘤负荷如何,通过免疫组织化学研究,所有12例HCL病例均在白血病细胞中显示出细胞质BRAF V600E蛋白表达,而所有HCL模仿病例(包括HCL-v,SMZL和MZL)均对BRAF V600E蛋白阴性。使用此BRAF V600E突变特异性抗体,此免疫组化研究对我们队列中的HCL诊断具有100%的敏感性和100%的特异性。总之,BRAF V600E突变蛋白的免疫组化检测对HCL的诊断具有高度的敏感性和特异性。与PCR或基于测序的方法相比,免疫组化是HCL及其模拟物之间鉴别诊断的相对快速和廉价的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号